ArticleAmerican journal of physiology. Heart and circulatory physiology2019
Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress.
Article in American journal of physiology. Heart and circulatory physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Genetic Animal Models of Cardiovascular Pathologies.Biomedicines · 2025Review
- Prolonged In Vivo Chemogenetic Generation of Hydrogen Peroxide by Endothelial Cells Induces Cardiac Remodelling and Vascular Dysfunction.Antioxidants (Basel, Switzerland) · 2025Article
- Gut microbiota-dependent increase in phenylacetic acid induces endothelial cell senescence during aging.Nature aging · 2025Article
- Advancing Neuroscience and Therapy: Insights into Genetic and Non-Genetic Neuromodulation Approaches.Cells · 2025Review
- AQP1 differentially orchestrates endothelial cell senescence.Redox biology · 2024Article
- Possible role of LCZ696 in atherosclerosis: new inroads and perspective.Molecular and cellular biochemistry · 2024Review
- FRBM Mini REVIEW: Chemogenetic approaches to probe redox dysregulation in heart failure.Free radical biology & medicine · 2024Review
- D-Amino acid oxidase-derived chemogenetic oxidative stress: Unraveling the multi-omic responses to in vivo redox stress.Current opinion in chemical biology · 2024Review
- Adult and neonatal models of chemogenetic heart failure caused by oxidative stress.The Journal of clinical investigation · 2024Article
- Targeting the redox system for cardiovascular regeneration in aging.Aging cell · 2023Review
- Rodent Models of Dilated Cardiomyopathy and Heart Failure for Translational Investigations and Therapeutic Discovery.International journal of molecular sciences · 2023Review
- Metabolomic and transcriptomic signatures of chemogenetic heart failure.American journal of physiology. Heart and circulatory physiology · 2022Article
- Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology.Annual review of pharmacology and toxicology · 2022Article
- Molecular mechanisms of sacubitril/valsartan in cardiac remodeling.Frontiers in pharmacology · 2022Review
- Complexities of the chemogenetic toolkit: Differential mDAAO activation by d-amino substrates and subcellular targeting.Free radical biology & medicine · 2021Article
- Dissecting in vivo and in vitro redox responses using chemogenetics.Free radical biology & medicine · 2021Review
- Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease.JACC. Basic to translational science · 2020Article
- Redox à la carte: Novel chemogenetic models of heart failure.British journal of pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
We previously described a novel "chemogenetic" animal model of heart failure that recapitulates a characteristic feature commonly found in human heart failure: chronic oxidative stress. This heart failure model uses a chemogenetic approach to activate a recombinant yeast d-amino acid oxidase in rat hearts in vivo to generate oxidative stress, which then rapidly leads to the development of a dilated cardiomyopathy. Here we apply this new model to drug testing by studying its response to treatment with the angiotensin II (ANG II) receptor blocker valsartan, administered either alone or with the neprilysin inhibitor sacubitril. Echocardiographic and [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.